Literature DB >> 11315256

Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue.

D Reissig1, J Clement, J Sänger, A Berndt, H Kosmehl, F D Böhmer.   

Abstract

Src-family kinase expression was measured in 52 human mammary tumor (T) specimens compared with non-tumor (NT) tissue from the same patient by enzymatic assays employing a Src-kinase family-specific peptide substrate and by immunoblotting with an antibody recognizing the Src-family kinases Src, Fyn, and Yes. In the T specimens, the mean enzymatic activity was moderately elevated (T: 160 fmol ATP min-1 mg-1; NT: 115 fmol ATP min-1 mg-1) with 25 tumor samples having higher activity than the corresponding NT tissue, 17 having lower activity, and no activity detectable in ten T/NT pairs. Immunoblotting revealed clearly elevated expression in 25 tumor tissues and no differences or expression below the detection limit in the remaining T/NT pairs. The data are in agreement with a possible role of Src-family kinases for the biology of mammary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315256     DOI: 10.1007/s004320000197

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.

Authors:  Murielle Glondu-Lassis; Mathilde Dromard; Magali Lacroix-Triki; Philippe Nirdé; Carole Puech; Dora Knani; Dany Chalbos; Gilles Freiss
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  DHHC20: a human palmitoyl acyltransferase that causes cellular transformation.

Authors:  Jeremiah M Draper; Charles D Smith
Journal:  Mol Membr Biol       Date:  2010-04       Impact factor: 2.857

3.  Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.

Authors:  Tapasree Roy Sarkar; Shikha Sharan; Jun Wang; Snehalata A Pawar; Carrie A Cantwell; Peter F Johnson; Deborah K Morrison; Ju-Ming Wang; Esta Sterneck
Journal:  Mol Cell Biol       Date:  2011-10-28       Impact factor: 4.272

Review 4.  Cancer-targeted therapies and radiopharmaceuticals.

Authors:  Tilman D Rachner; Franz Jakob; Lorenz C Hofbauer
Journal:  Bonekey Rep       Date:  2015-06-03

Review 5.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.

Authors:  John Araujo; Christopher Logothetis
Journal:  Cancer Treat Rev       Date:  2010-03-11       Impact factor: 12.111

Review 6.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

7.  Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells.

Authors:  Jae K Lee; Kimberly J Bussey; Fuad G Gwadry; William Reinhold; Gregory Riddick; Sandra L Pelletier; Satoshi Nishizuka; Gergely Szakacs; Jean-Phillipe Annereau; Uma Shankavaram; Samir Lababidi; Lawrence H Smith; Michael M Gottesman; John N Weinstein
Journal:  Genome Biol       Date:  2003-11-25       Impact factor: 13.583

8.  SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Authors:  Adina Vultur; Ralf Buettner; Claudia Kowolik; Wei Liang; David Smith; Frank Boschelli; Richard Jove
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

9.  miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth.

Authors:  Ning Wang; Qi Li; Ning-Han Feng; Gong Cheng; Zhao-Long Guan; Yang Wang; Chao Qin; Chang-Jun Yin; Li-Xin Hua
Journal:  Asian J Androl       Date:  2013-08-26       Impact factor: 3.285

10.  Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.

Authors:  Thorsten Heilmann; Anna-Lena Rumpf; Marijke Roscher; Maren Tietgen; Olga Will; Mirko Gerle; Timo Damm; Christoph Borzikowsky; Nicolai Maass; Claus-Christian Glüer; Sanjay Tiwari; Anna Trauzold; Christian Schem
Journal:  Arch Gynecol Obstet       Date:  2020-03-14       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.